Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib

Current Medical Research and Opinion

Volumn 27, Issue 12, 2011, Pages 2245-2252

  Sherrill, Beth ^a   Sherif, Bintu ^a   Amonkar, Mayur M ^b   Maltzman, Julie ^b   O'Rourke, Lisa ^b   Johnston, Stephen ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; HER2; Lapatinib; Letrozole; Metastatic; Q TWIST; Quality adjusted

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PLACEBO;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; METASTATIC BREAST CANCER; MULTICENTER STUDY; NAIL DISEASE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; SURVIVAL RATE; TRIAZOLES;

EID: 81855184897     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.621209     Document Type: Article

References (26)

1. Carlson RW. NCCN breast cancer clinical practice guidelines in oncology: an update. J Natl Compr Canc Netw 2003;1:S61-3
2. Arpino G, Weichmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family. Endocr Rev 2008; 29:217-33
3. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ErbB2 by estrogen receptor-PAX2 determines response to tamoxifen. Nature 2008;456:663-6
4. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967-72
5. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:9-15
6. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004;10:3621-8
7. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
8. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
9. Schwarzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as firstline therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
10. Bernard-Marty C, Lebrun F, Awada A, et al. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006;66:1577-91
11. Piccart MJ, de Valeriola D, Dal Lago L, et al. Adjuvant chemotherapy in 2005: standards and beyond. Breast 2005;14:439-45
12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - breast cancer. V.1. 2010. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf [Last accessed March 2010]
13. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52
14. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006;355:2733-43
15. Sherif BN, Sherrill B, Amonkar M, et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer: a quality of life analysis. Poster presented at the American Society of Clinical Oncology Annual Meeting, Orlando, FL, USA, May-June 2009
16. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics 1989;45:781-95
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
18. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990;9:1259-76
19. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17
20. Sherrill B, Amonkar MM, Sherif B, et al. An exploration of the association of QOL scores with tumor progression status in first-line HR+, HER2+ MBC patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the 32nd San Antonio Breast Cancer Symposium Annual Meeting, San Antonio, TX, USA, December 2009
21. GlaxoSmithKline. Tykerb: highlights of prescribing information. 2010. Available at: http:/www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022059s3s6lbl.pdf [Last accessed 1 Apr 2010]
22. Sherrill B, DiLeo A, Amonkar M, et al. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin 2010;26:767-75
23. Kataja V, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19:ii11-3
24. Gee JM, Harper ME, Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105-17
25. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-33
26. Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008;99:711-15